Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Saulius Girnius

Showing results (11-20 of 16) with videos related to

Pageof 2
Sort By:
You have reached the last page of results.This site can display upto 16 results.
Blood|September 9, 2025
Isatuximab for relapsed and/or refractory AL amyloidosis: results of a prospective phase 2 trial (SWOG S1702)Terri L Parker, Adam Rosenthal, Vaishali Sanchorawala, et al.
Future Oncology (London, England)|October 9, 2023
<i>In</i>-class transition from bortezomib-based therapy to IRd is an effective approach in newly diagnosed multiple myelomaRobert M Rifkin, Caitlin L Costello, Ruemu E Birhiray, et al.
Hematological Oncology|February 14, 2020
Final analysis of a phase 1/2b study of ibrutinib combined with carfilzomib/dexamethasone in patients with relapsed/refractory multiple myelomaAjai Chari, Robert F Cornell, Cristina Gasparetto, et al.
Clinical Lymphoma, Myeloma & Leukemia|September 11, 2020
Feasibility of Long-term Proteasome Inhibition in Multiple Myeloma by in-class Transition From Bortezomib to IxazomibSudhir Manda, Habte A Yimer, Stephen J Noga, et al.
Heart (British Cardiac Society)|November 25, 2020
Bleeding and thrombotic risk in pregnant women with Fontan physiologyAndrea Girnius, Dominica Zentner, Anne Marie Valente, et al.
Leukemia|April 22, 2020
Hematopoietic cell transplantation utilization and outcomes for primary plasma cell leukemia in the current eraBinod Dhakal, Sagar Patel, Saulius Girnius, et al.
Pageof 2

Showing results (11-20 of 16) with videos related to

Sort By:
Pageof 2
You have reached the last page of results.This site can display upto 16 results.
Blood|September 9, 2025
Isatuximab for relapsed and/or refractory AL amyloidosis: results of a prospective phase 2 trial (SWOG S1702)Terri L Parker, Adam Rosenthal, Vaishali Sanchorawala, et al.
Future Oncology (London, England)|October 9, 2023
<i>In</i>-class transition from bortezomib-based therapy to IRd is an effective approach in newly diagnosed multiple myelomaRobert M Rifkin, Caitlin L Costello, Ruemu E Birhiray, et al.
Hematological Oncology|February 14, 2020
Final analysis of a phase 1/2b study of ibrutinib combined with carfilzomib/dexamethasone in patients with relapsed/refractory multiple myelomaAjai Chari, Robert F Cornell, Cristina Gasparetto, et al.
Clinical Lymphoma, Myeloma & Leukemia|September 11, 2020
Feasibility of Long-term Proteasome Inhibition in Multiple Myeloma by in-class Transition From Bortezomib to IxazomibSudhir Manda, Habte A Yimer, Stephen J Noga, et al.
Heart (British Cardiac Society)|November 25, 2020
Bleeding and thrombotic risk in pregnant women with Fontan physiologyAndrea Girnius, Dominica Zentner, Anne Marie Valente, et al.
Leukemia|April 22, 2020
Hematopoietic cell transplantation utilization and outcomes for primary plasma cell leukemia in the current eraBinod Dhakal, Sagar Patel, Saulius Girnius, et al.
Pageof 2